Lacutamab (IPH4102)

About Innate Pharma

Innate Pharma is a pioneer in leveraging innate immunity, particularly natural killer (NK) cells, to develop next-generation antibody therapeutics for oncology. Its strategy is built on a diversified pipeline of potentially first- or best-in-class assets, including the Phase 3-ready lacutamab for T-cell lymphomas and the Nectin-4 ADC IPH4502, supported by proprietary platforms like ANKET® and key collaborations with Sanofi and AstraZeneca. Despite a challenging financial position with a low market valuation, the company's near-term value inflection hinges on the clinical and regulatory progress of its lead candidate, lacutamab, which holds Breakthrough Therapy Designation.

About Innate Pharma

Innate Pharma is a pioneer in leveraging innate immunity, particularly natural killer (NK) cells, to develop next-generation antibody therapeutics for oncology. Its strategy is built on a diversified pipeline of potentially first- or best-in-class assets, including the Phase 3-ready lacutamab for T-cell lymphomas and the Nectin-4 ADC IPH4502, supported by proprietary platforms like ANKET® and key collaborations with Sanofi and AstraZeneca. Despite a challenging financial position with a low market valuation, the company's near-term value inflection hinges on the clinical and regulatory progress of its lead candidate, lacutamab, which holds Breakthrough Therapy Designation.

Therapeutic Areas